Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
King's College London · King's College Hospital · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH).
Aims
To describe the trial design and baseline characteristics of the 'Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis' (ESSENCE) trial (NCT04822181).
Citation impact
117
total citations
- FWCI
- 41.19
- Percentile
- 100%
- References
- 27
Citations per year
Authors
10Topics & keywords
Topics
Keywords
- Medicine
- Steatohepatitis
- Internal medicine
- Semaglutide
- Gastroenterology
- Fatty liver
- Population
- Placebo
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.